Alida Biosciences Launches EpiPlex® Tri-Mod™ Service for Simultaneous Profiling of Three Key mRNA Modifications

SAN DIEGO, April 15, 2026 /PRNewswire/ -- Alida Biosciences today announced the launch of its EpiPlex™ Tri-Mod™ Service, enabling simultaneous detection and quantification of three key mRNA modifications—N6-methyladenosine (m6A), inosine, and pseudouridine—together with RNA expression...